奥氮平治疗精神分裂症对患者糖脂代谢及血常规结果的影响

doi:10.3969/j.issn.1671-7171.2025.02.022

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1183 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To investigate the impact of olanzapine treatment on glycolipid metabolism and blood routine test results in patients with schizophrenia (SCZ).【Methods】A total of 230 SCZ patients were divided into the observation group (118 patients, treated with olanzapine) and the control group (112 patients, treated with risperidone) based on different treatment plans. The efficacy and the changes of glycolipid metabolism and blood routine indicators before and after treatment were compared between the two groups.【Results】The clinical efficacy in the observation group was higher than that in the control group, however, the difference was not statistically significant (P>0.05). After treatment, the scores of the Positive and Negative Syndrome Scale (PANSS) on all dimensions in the observation group were significantly lower than those in the control group (P<0.05). After treatment, the fasting plasma glucose (FPG), total cholesterol (TC), and low-density lipoprotein cholesterol (LDL-C) levels in both groups were significantly lower than before (P<0.05), while triglyceride (TG) level significantly increased (P<0.05). Moreover, the levels of these indicators were significantly lower in the observation group than those in the control group (P<0.05). There were no statistically significant differences in blood routine test results between the two groups before and after treatment (P>0.05).【Conclusion】Olanzapine and risperidone have similar overall therapeutic effects on SCZ patients. However, olanzapine has a more significant advantage in improving glycolipid metabolism and it does not have adverse effects on blood routine indicators.

Key words： Schizophrenia Olanzapine Glycolipids

Received: 15 August 2024

PACS:

R749.3

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	CHENG Weihong

Cite this article:

CHENG Weihong. The Effect of Olanzapine on Glycolipid Metabolism and Blood Routine Results in Schizophrenia Patients[J]. JOURNAL OF CLINICAL RESEARCH, 2025, 42(2): 252-254.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2025.02.022 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2025/V42/I2/252

[1] 张秀丽, 刘旭恩, 王硕, 等. 认知行为治疗联合注意力训练对精神分裂症幻听干预效果的随机对照试验[J].中国心理卫生杂志, 2024, 38(3):206-212.
[2] 王天乐, 李日照, 黄啟洋, 等. 奥尔夫音乐疗法对精神分裂症长期住院患者干预研究[J].中国神经精神疾病杂志, 2024, 50(3):135-139.
[3] 罗传琳, 李媛媛, 刘肇瑞, 等. 精神分裂症、抑郁症、双相障碍患者自杀风险比较及相关因素[J].中国心理卫生杂志, 2024, 38(1):1-8.
[4] 郭年春, 王婧, 于欣. 事件相关电位对精神分裂症高危人群早期识别及转化研究(综述)[J].中国心理卫生杂志, 2024, 38(3):200-205.
[5] 郑东翠, 阚博, 朱柏, 等. 阿立哌唑联合奥氮平对精神分裂症患者糖脂代谢及内分泌功能影响的研究[J].临床和实验医学杂志, 2024, 23(7):702-705.
[6] 卿剑明, 李建国, 张红艳, 等. 首次确诊精神分裂症患者认知功能损害情况分析[J].医学临床研究, 2018, 35(5):912-914.
[7] 叶景恒, 唐京雄, 钟薛芬. 奥氮平与阿立哌唑治疗精神分裂症的效果及安全性比较[J].临床合理用药杂志, 2022, 15(10):60-63.
[8] 侯慧珍, 杨萍, 杨竞闻, 等. 成年男性精神分裂症杏仁核神经代谢物与PANSS评分的相关性[J].国际精神病学杂志, 2024, 51(3):689-693.
[9] JAIN A K, SHAH A, BHAT G.Olanzapine-induced diabetic ketoacidosis: a reversible etiology overlooked in psychiatric patients[J].AACE Clin Case Rep,2024, 10(1):14-16.
[10] HUANG P P, RAN J L, ZHU W Q,et al. PCSK9 dysregulates cholesterol homeostasis and triglyceride metabolism in olanzapine-induced hepatic steatosis via both receptor-dependent and receptor-independent pathways[J].FASEB J,2024, 38(4):e23464.
[11] ZUO Y F, ZHANG B H, GUO M R,et al. HFD-exacerbated metabolic side effects of olanzapine are suppressed by ER stress inhibitor[J].Cur Med Sci,2023, 43(6):1116-1132.
[12] 中华医学会精神医学分会精神分裂症协作组. 注射用利培酮微球临床应用专家共识[J].中国心理卫生杂志,2023,37(8):641-647.
[13] 吕蔚,郑志友,王茵. 小剂量奥氮平联合帕罗西汀治疗重性抑郁症急性期的疗效观察[J].国际精神病学杂志,2024,51(3):819-821.